

DAFTAR PUSTAKA

- American Psychiatric Association, 2006. *APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches*, 1st ed. American Psychiatric Association, Arlington, VA.
- Andayani, T.M., 2013. *Farmakoekonomi: Prinsip & Metodologi*. Bursa Ilmu, Yogyakarta.
- Auffarth, I., Busse, R., Dietrich, D., dan Emrich, H., 2008. Length of Psychiatric Inpatient Stay: Comparison of Mental Health Care Outlining a Case Mix From a Hospital in Germany and the United States of America. *German Journal of Psychiatry*, **11**: 40–44.
- Barnett, A.H., Millar, H.L., Loze, J.-Y., l'Italian, G.J., Baardewijk, M.V., dan Knapp, M., 2009. UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study). *European Archives of Psychiatry and Clinical Neuroscience*, **259**: 239–247.
- Buchanan, R.W. dan Carpenter, Jr., W.T., 2000. Schizophrenia: Introduction and Overview, dalam: Sadock, B.J., Sadock, V.A. (Eds.), *Kaplan & Sadock's Comprehensive Textbook of Psychiatry*. Lippincott Williams & Wilkins, New York.
- Cancro, R. dan Lehmann, H.E., 2000. Schizophrenia: Clinical Features, dalam: Sadock, B.J., Sadock, V.A. (Eds.), *Kaplan & Sadock's Comprehensive Textbook of Psychiatry*. Lippincott Williams & Wilkins, New York.
- Cassano, G.B., Fagiolini, A., Lattanzi, L., Monteleone, P., Niolu, C., Sacchetti, E., dkk., 2007. Aripiprazole in the Treatment of Schizophrenia. *Clin Drug Invest*, **27**: 1–13.
- Crismon, M.L. dan Buckley, P.F., 2005. Schizophrenia, dalam: DiPiro, J.T., Talbert, R.L., Yee, G.C., Matzke, G.R., Wells, B.G., Posey, L.M. (Eds.), *Pharmacotherapy: A Pathophysiologic Approach*. McGraw-Hill, United State of America, hal. 1209–1230.
- Deister, A. dan Marneros, A., 1993. Long-term stability of subtypes in schizophrenic disorders: a comparison of four diagnostic systems. *Eur Arch Psychiatry Clin Neurosci*, **242**: 184–190.
- Desai, P.R., Lawson, K.A., Barner, J.C., dan Rascati, K.L., 2013. Identifying Patient Characteristics Associated with High Schizophrenia-Related Direct Medical Cost in Community-Dwelling Patient. *Journal of Managed Care Pharmacy*, **19**: .
- Dixon, L., Lyles, A., Smith, C., Hoch, J.S., Fahey, M., Postardo, L., dkk., 2001. Use and Costs of Ambulatory Care Services Among Medicare Enrollees With Schizophrenia. *Psychiatric Services*, **52**: .

Dyah, R.I., 2013. 'Analisis Biaya Terapi Pasien Diabetes Melitus Rawat Inap RSUD Dr. Moewardi Surakarta Periode Tahun 2010'. Gadjah Mada, Yogyakarta.

Endarti, D., 2004. 'Profil Penggunaan Obat dan Analisis Biaya Terapi Pada Pasien Diare Anak Yang Menjalani Rawat Inap di RS PKU Muhammadiyah Yogyakarta Tahun 2004'. Gadjah Mada, Yogyakarta.

Endow-Eyer, R.A., Mitchell, M.M., dan Lacro, J.P., 2009. Schizophrenia, dalam: Koda-Kimble, M.A., Young, L.Y., Alldredge, B.K., Corelli, R.L., Guglielmo, B.J., Kradjan, W.A., dkk. (Eds.), *Applied Therapeutics : The Clinical Use Of Drugs*. Lippincot Williams & Wilkins, United State of America.

Fenton, W.. dan McGlashan, T., 1991. Natural history of schizophrenia subtypes. I. Longitudinal study of paranoid, hebephrenic, and undifferentiated schizophrenia. *Archives of General Psychiatry*, **48**: 969 – 977.

Furiak, N.M., Ascher-Svanum, H., Klein, R.W., Smolen, L.J., Lawson, A.H., Conley, R.R., dkk., 2009. Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States. *Cost Effectiveness and Resource Allocation*, **7**: 4.

Gani, A., 1996. Analisis Biaya Rumah Sakit. *Makalah Seri Manajemen Keuangan Pelayanan Kesehatan*, .

Guest, J.F. dan Cookson, R.F., 1999. Cost of Schizophrenia to UK Society. *PharmacoEconomics*, **15**: 597–610.

Häfner, H. dan Heiden, W. an der, 1997. Epidemiology of Schizophrenia. *The Canadian Journal of Psychiatry*, **42**: 139–151.

Haycox, A., Boland, A., dan Walley, T., 2004. Basics of economics, health economics and pharmacoeconomics, dalam: Walley, T., Haycox, A., Boland, A. (Eds.), *Pharmacoeconomics*. Elsevier Science, Spain.

Heckers, S. dan Berretta, S., 2005. Schizophrenia, dalam: Tarazi, F.I., Schetz, J.A. (Eds.), *Neurological and Psychiatric Disorders*. Humana Press, New Jersey, hal. 111–128.

Henigsberg, N. dan Folnegovic-Smalc, V., 2002. Frequency and Length of Schizophrenia Admissions: Analysis By ICD-10 Defined Subtypes. *Druš. Istraž. Zagreb God.*, **11**: 113–131.

Huntley, D.A., Cho, D.W., Christman, J., dan Csernansky, J.G., 1998. Predicting length of stay in an acute psychiatric hospital. *Psychiatric Services (Washington, D.C.)*, **49**: 1049–1053.

Jenderal Bina Kefarmasian dan Alat Kesehatan, 2013. *Pedoman Penerapan Kajian Farmakoekonomi*. Kementrian Kesehatan Republik Indonesia, Jakarta.

Jiménez, R.E., Lam, R.M., Marot, M., dan Delgado, A., 2004. Observed-predicted length of stay for an acute psychiatric department, as an indicator of inpatient

care inefficiencies. Retrospective case-series study. *BMC Health Services Research*, **4**: 4.

Kamat, S.A., Blanchette, C.M., Wilson, M., Tangirala, M., Earnshaw, S., Offord, S., dkk., 2014. *Healthcare Cost Savings Associated With Aripiprazole Once-Monthly (AOM) Treatment Among Schizophrenia Patients With Psychiatric Hospitalizations Prior to AOM Treatment Initiation*.

Kasper, D.L., Braunwald, E., Fauci, A.S., Hauser, S.L., Longo, D.L., dan Jameson, J.L. (Eds.), 2005. *Harrison's Manual of Medicine*. McGraw-Hill, New Jersey.

Knapp, M., Mangalore, R., dan Simon, J., 2004. The Global Costs of Schizophrenia. *Schizophrenia Bulletin*, **30**: 279–293.

Lage, M.J. dan Rajagoplan, K., 2006. Hospitalization and Emergency Department Visits Among Patients Treated with Atypical Antipsychotics: Evidence from a Commercially Insured Population. *The Journal of Applied Research*, **6**: 115–125.

Maslim, R., 2001. *Diagnosis Gangguan Jiwa, Rujukan Ringkas PPDGJ-III*. Bagian Ilmu Kedokteran jiwa FK Unika Atmajaya, Jakarta.

McCombs, J.S., Nichol, M.B., Johnstone, B.M., Stimmel, G.L., Shi, J., dan Smith, R., 2000. Antipsychotic Drug Use Patterns and the Cost of Treating Schizophrenia. *Psychiatric Services*, **51**: 525–527.

Mills, A., Vaughan, J.P., Smith, D.L., Tabibzadeh, I., dan World Health Organization, 1990. *Health System Decentralization: Concepts, Issues and Country Experience*. World Health Organization, Geneva.

Mladi, D.M., Grogg, A.L., Irish, W.D., Lopez, R.B., Degen, K., Swann, A., dkk., 2004. Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings. *Current Medical Research & Opinion*, **20**: 1883–1893.

Peiró, S., Gómez, G., Navarro, M., Guadarrama, I., Rejas, J., dan Group*, for the P., 2004. Length of stay and antipsychotic treatment costs of patients with acute psychosis admitted to hospital in Spain. *Social Psychiatry and Psychiatric Epidemiology*, **39**: 507–513.

Perwira, I., 2011. 'Faktor-Faktor Yang Mempengaruhi Lama Rawat Inap Pada Pasien Yang Terinfeksi Virus Dengue Di RSUP Persahabatan - Jakarta Timur'. Indonesia, Depok.

Phanthunane, P., Vos, T., Whiteford, H., dan Bertram, M., 2011. Cost-effectiveness of pharmacological and psychosocial interventions for schizophrenia. *Cost Effectiveness and Resource Allocation*, **9**: 6.

Piccinelli, M. dan Homen, F.G., 1997. *Genders Differences in the Epidemiology of Affective Disorders and Schizophrenia*. World Health Organization, Geneva.

Reus, V.I., 2005. Psychiatric Disorders, dalam: Kasper, D.L., Fauci, A.S., Longo, D.L., Braunwald, E., Hauser, S.L., Jameson, J.L. (Eds.), *Harrison's Principles Of Internal Medicine*. McGraw-Hill, United State of America, hal. 2559–2561.

'Riset Kesehatan Dasar (Riskesdas)', 2013. URL: <http://www.riskesdas.litbang.depkes.go.id/bloksensus.htm> (diakses tanggal 12/9/2014).

Rosenheck, R., Cramer, J., Xu, W., Thomas, J., Henderson, W., Frisman, L., dkk., 1997. A Comparison of Clozapine and Haloperidol in Hospitalized Patients with Refractory Schizophrenia. *New England Journal of Medicine*, **337**: 809–815.

Sadock, B.J., 2000. *Kaplan & Sadock's Comprehensive Textbook of Psychiatry (2 Volume Set)*. Lippincott Williams & Wilkins.

Sanchez, L.A., 2005. Pharmacoeconomics: Principles, Methods, And Applications, dalam: DiPiro, J.T., Talbert, R.L., Yee, G.C., Matzke, G.R., Wells, B.G., Posey, L.M. (Eds.), *Pharmacotherapy: A Pathophysiologic Approach*. McGraw-Hill, United State of America.

Sartorius, N., Fleischhacker, W., Gjerris, A., Kern, U., Knapp, M., Leonhard, B.E., dkk., 2002. The usefulness and use of second-generation antipsychotic medications/an update. *Curr Opin Psychiatry*, **15**: S1A.

Stahl, S.M., 2008. *StahFs Essential Psychopharmacology : Neuroscientific Basis and Practical Applications*, 3rd ed. Cambridge University Press, United State of America.

Wells, B.G. (Ed.), 2009. Schizophrenia, dalam: *Pharmacotherapy Handbook*. McGraw-Hill, New York.

WHO, 2009. *Pharmacological Treatment of Mental Disorders in Primary Health Care*, WHO Guidelines Approved by the Guidelines Review Committee. World Health Organization, Geneva.

WHO, 2010. *ICD-10: The International Statistical Classification of Disease and Health Related Problems*, 2nd ed. World Health Organization, Geneva.

'WHO | Schizophrenia', 2014. WHO. URL: http://www.who.int/mental_health/management/schizophrenia/en/ (diakses tanggal 18/9/2014).

Zaprutko, T., Nowakowska, E., Kus, K., Bilobryvka, R., Rakhman, L., dan Pogłodziński, A., 2015. The Cost of Inpatient Care of Schizophrenia in the Polish and Ukrainian Academic Centers -Poznan and Lviv. *Acad Psychiatry*, **39**: 165–173.